Buying Generic: An Underrated Comp for a Budding Star
As a RotoGraphs reader, I’ve always enjoyed Joe Douglas’s “Buying Generic” series. In past articles, he has compellingly compared “generic” players like Ryon Healy, Logan Forsythe, and Justin Bour to “brand name” ones like Jake Lamb, Jason Kipnis, and Carlos Santana.
The fantasy relevance of the exercise is obvious: Buying generic allows owners to acquire players cheaply and with relative ease, instead of paying a premium (whether in a trade or in a draft or auction) for a brand-name player.
For today’s comparison, we’re going to analyze two players who have played in parts of the last three seasons, but neither has eclipsed 350 plate appearances in any one year. Both appear on their way to full-time jobs in 2017 and beyond.
Here’s how Mr. Generic and Mr. Brand Name have fared since 2015:
Name | PA | BB% | K% | AVG | OBP | SLG | ISO | BABIP | wOBA | wRC+ |
---|---|---|---|---|---|---|---|---|---|---|
Mr. Generic | 438 | 11.0% | 29.9% | .262 | .350 | .486 | .223 | .346 | .357 | 124 |
Mr. Brand Name | 715 | 10.6% | 23.9% | .258 | .343 | .497 | .239 | .298 | .355 | 125 |